Although Sanofi (NYSE:SNY) has not always gotten the attention that other major pharmas have drawn for their respective restructuring efforts, Sanofi has changed in some meaningful respects over the past few years. The company could still handle some of its internal operations a bit better, and there are definitely still some challenges to its revenue base, but investors would do well to consider one of the largest pharmaceutical companies in the world for their portfolios.
The Good
Sanofi certainly has the scale that it takes to compete in the modern global pharmaceuticals market, as this is not only the fifth-largest drug company, but also one that is well-balanced between markets in the United States and non-U.S. markets. Moreover, the company has a sizable vaccines franchise and has been reinvesting capital in ancillary divisions like consumer health and animal care. (For related reading, see A Primer On The Biotech Sector.)
Please click here for me:
http://stocks.investopedia.com/stock-analysis/2011/Sanofis-Investment-Prospects-SNY-NVS-LLY-NVO-BIIB-TEVA-REGN1221.aspx
No comments:
Post a Comment